$4.95 Billion is the total value of NEA Management Company, LLC's 58 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
BHG | BRIGHT HEALTH GROUP INC | $750,650,000 | -57.8% | 218,212,128 | 0.0% | 15.17% | -28.3% | |
COUR | COURSERA INC | $387,808,000 | -22.8% | 15,867,769 | 0.0% | 7.84% | +31.4% | |
BERKSHIRE GREY INC | $210,246,000 | -21.8% | 38,226,621 | 0.0% | 4.25% | +33.1% | ||
GLUE | MONTE ROSA THERAPEUTICS INC | $157,299,000 | -8.3% | 7,703,205 | 0.0% | 3.18% | +55.9% | |
CRSP | CRISPR THERAPEUTICS AGnamen akt | $120,490,000 | -32.3% | 1,590,002 | 0.0% | 2.44% | +15.2% | |
OYST | OYSTER PT PHARMA INC | $108,196,000 | +54.1% | 5,925,287 | 0.0% | 2.19% | +162.2% | |
DM | DESKTOP METAL INC | $71,318,000 | +590.4% | 14,407,594 | 0.0% | 1.44% | +1071.5% | |
MIRM | MIRUM PHARMACEUTICALS INC | $66,795,000 | -19.9% | 4,187,801 | 0.0% | 1.35% | +36.2% | |
ADAP | ADAPTIMMUNE THERAPEUTICS PLCadr | $64,060,000 | -27.5% | 17,082,611 | 0.0% | 1.30% | +23.5% | |
RYTM | RHYTHM PHARMACEUTICALS INC | $49,025,000 | -23.6% | 4,912,306 | 0.0% | 0.99% | +30.1% | |
NKTX | NKARTA INC | $44,591,000 | -44.8% | 2,904,974 | 0.0% | 0.90% | -6.1% | |
CSPR | CASPER SLEEP INC | $41,591,000 | +56.4% | 6,226,130 | 0.0% | 0.84% | +166.1% | |
RPHM | RENEO PHARMACEUTICALS INC | $40,928,000 | +14.8% | 4,786,921 | 0.0% | 0.83% | +95.0% | |
AKUS | AKOUOS INC | $36,537,000 | -26.8% | 4,298,488 | 0.0% | 0.74% | +24.5% | |
VRNA | VERONA PHARMA PLCads | $34,330,000 | +22.8% | 5,108,563 | 0.0% | 0.69% | +109.0% | |
VTGN | VISTAGEN THERAPEUTICS INC | $31,790,000 | -28.8% | 16,302,596 | 0.0% | 0.64% | +20.9% | |
SVRA | SAVARA INC | $29,931,000 | -10.1% | 24,137,931 | 0.0% | 0.60% | +52.8% | |
CVRX | CVRX INC | $28,996,000 | -92.6% | 2,370,858 | 0.0% | 0.59% | -87.4% | |
AFMD | AFFIMED NV | $24,434,000 | -10.7% | 4,426,488 | 0.0% | 0.49% | +52.0% | |
EAR | EARGO INC | $23,055,000 | -24.2% | 4,520,670 | 0.0% | 0.47% | +29.1% | |
MEIP | MEI PHARMA INC | $22,783,000 | -3.3% | 8,533,072 | 0.0% | 0.46% | +64.3% | |
ALLK | ALLAKOS INC | $21,192,000 | -90.8% | 2,164,704 | 0.0% | 0.43% | -84.3% | |
MILE | METROMILE INC | $20,552,000 | -38.3% | 9,384,285 | 0.0% | 0.42% | +4.8% | |
AVEO | AVEO PHARMACEUTICALS INC | $18,539,000 | -24.1% | 3,952,958 | 0.0% | 0.38% | +29.3% | |
BDTX | BLACK DIAMOND THERAPEUTICS INC | $18,388,000 | -37.0% | 3,449,845 | 0.0% | 0.37% | +7.2% | |
IVA | INVENTIVA SAads | $17,740,000 | -3.5% | 1,298,700 | 0.0% | 0.36% | +64.7% | |
CTIC | CTI BIOPHARMA CORP | $17,708,000 | -15.9% | 7,140,450 | 0.0% | 0.36% | +43.2% | |
PHAS | PHASEBIO PHARMACEUTICALS INC | $17,340,000 | -16.1% | 6,643,704 | 0.0% | 0.35% | +42.9% | |
INZY | INOZYME PHARMA INC | $16,671,000 | -41.2% | 2,444,379 | 0.0% | 0.34% | 0.0% | |
GERN | GERON CORP | $16,423,000 | -10.9% | 13,461,538 | 0.0% | 0.33% | +51.6% | |
CSBR | CHAMPIONS ONCOLOGY INC | $14,327,000 | -18.1% | 1,713,720 | 0.0% | 0.29% | +39.4% | |
STSA | SATSUMA PHARMACEUTICALS INC | $14,143,000 | -3.4% | 3,142,958 | 0.0% | 0.29% | +64.4% | |
GLYC | GLYCOMIMETICS INC | $13,088,000 | -34.2% | 9,089,041 | 0.0% | 0.26% | +11.9% | |
GNCA | GENOCEA BIOSCIENCES INC | $12,037,000 | -39.6% | 10,376,936 | 0.0% | 0.24% | +2.5% | |
SYBX | SYNLOGIC INC | $10,235,000 | -20.7% | 4,229,410 | 0.0% | 0.21% | +35.3% | |
MRKR | MARKER THERAPEUTICS INC | $10,179,000 | -43.8% | 10,714,285 | 0.0% | 0.21% | -4.2% | |
LXRX | LEXICON PHARMACEUTICALS INC | $9,386,000 | -18.1% | 2,382,286 | 0.0% | 0.19% | +39.7% | |
OBSV | OBSEVA SA | $9,127,000 | -36.0% | 4,586,563 | 0.0% | 0.18% | +8.9% | |
TRVI | TREVI THERAPEUTICS INC | $4,634,000 | -44.3% | 5,940,796 | 0.0% | 0.09% | -5.1% | |
RGLS | REGULUS THERAPEUTICS INC | $2,064,000 | -53.7% | 6,451,056 | 0.0% | 0.04% | -20.8% | |
TCON | TRACON PHARMACEUTICALS INC | $960,000 | -28.5% | 346,718 | 0.0% | 0.02% | +18.8% | |
AKTX | AKARI THERAPEUTICS PLCadr | $678,000 | -8.0% | 452,167 | 0.0% | 0.01% | +55.6% | |
TPST | TEMPEST THERAPEUTICS INC | $622,000 | -63.5% | 117,785 | 0.0% | 0.01% | -35.0% | |
ADXN | ADDEX THERAPEUTICS LTDsponsored ads | $205,000 | -87.4% | 180,000 | 0.0% | 0.00% | -78.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
TREVENA INC | 31 | Q3 2021 | 3.3% |
AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
ARDELYX INC | 29 | Q3 2021 | 11.9% |
RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-10 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.